<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
NATHBIOGEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Nath Bio-Genes has filed a confirmation with BSE and NSE stating that as of 31st March 2026, it does not meet the criteria to be classified as a 'Large Corporate' under SEBI guidelines. The company has NIL outstanding long-term borrowing and no listed debt securities or non-convertible redeemable preference shares. Its highest credit rating is BBB+ from India Ratings and Research, which is below the AA threshold specified in the circular. The filing is a routine regulatory compliance confirming the company's exclusion from Large Corporate status and the associated mandatory capital market spend requirements.
No direct shareholder impact — this is a routine regulatory confirmation. The company avoids Large Corporate obligations due to low debt levels and absence of listed debt instruments.